Jefferies Financial Group lowered shares of ESSA Pharma (NASDAQ:EPIX - Free Report) TSE: EPI from a buy rating to a hold rating in a report published on Monday morning, Marketbeat.com reports.
A number of other research analysts have also recently weighed in on the company. Oppenheimer cut ESSA Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday. Piper Sandler cut shares of ESSA Pharma from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $15.00 to $2.00 in a research report on Monday.
Check Out Our Latest Stock Report on EPIX
ESSA Pharma Stock Performance
EPIX stock traded up $0.23 during trading on Monday, reaching $1.63. 5,970,394 shares of the company were exchanged, compared to its average volume of 273,230. The stock's 50 day moving average price is $5.88 and its 200 day moving average price is $5.68. ESSA Pharma has a 52-week low of $1.40 and a 52-week high of $11.67. The company has a market cap of $72.32 million, a P/E ratio of -2.63 and a beta of 1.84.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.10. As a group, equities research analysts forecast that ESSA Pharma will post -0.71 EPS for the current year.
Institutional Trading of ESSA Pharma
An institutional investor recently bought a new position in ESSA Pharma stock. EntryPoint Capital LLC bought a new position in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,420 shares of the company's stock, valued at approximately $38,000. Hedge funds and other institutional investors own 75.12% of the company's stock.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Articles
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
